Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Low molecular weight heparins]

L Drouet1

  • 1Laboratoire d'Hématologie, Hôpital Raymond Poincaré, Garches.

Presse Medicale (Paris, France : 1983)
|December 18, 1993
PubMed
Summary
This summary is machine-generated.

Low molecular weight heparins (LMWH) are preferred in France for deep vein thrombosis (DVT) prevention and treatment due to effectiveness and ease of use. Established benefits include DVT prevention and treatment, with ongoing research clarifying remaining clinical questions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

French National Diagnostic and Care Protocol for antiphospholipid syndrome in adults and children.

La Revue de medecine interne·2023
Same author

Anticoagulant activity and pleiotropic effects of heparin.

Journal de medecine vasculaire·2020
Same author

Determinants of aspirin resistance in patients with type 2 diabetes.

Diabetes & metabolism·2019
Same author

[ST elevation myocardial infarction in young adults: Is there an interest for thrombophilia screening?]

Annales de cardiologie et d'angeiologie·2018
Same author

[Involvement of thrombophilia in coronary thrombosis].

Annales de cardiologie et d'angeiologie·2017
Same author

Mycobacterium bovis BCG killed by extended freeze-drying induces an immunoregulatory profile and protects against atherosclerosis.

Journal of internal medicine·2013
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

Area of Science:

  • Pharmacology
  • Thrombosis Management
  • Clinical Practice Guidelines

Context:

  • Low molecular weight heparins (LMWH) are widely used in France.
  • French physicians show a preference for LMWH over standard heparin.
  • LMWH use is common for deep vein thrombosis (DVT) prevention and increasingly for treatment.

Purpose:

  • To review the established, accepted, and debatable clinical uses of LMWH.
  • To differentiate evidence-based practices from ongoing clinical questions regarding LMWH.
  • To provide an update on LMWH efficacy and safety in various clinical scenarios.

Summary:

  • LMWH is established for DVT prevention in general, orthopedic surgery, and medicine, as well as for DVT treatment.
  • Accepted but not fully established benefits include a better risk/efficiency ratio than standard heparin, lower risk of heparin-induced thrombocytopenia, and safety in pregnancy.

Related Experiment Videos

  • Unresolved questions include the need for anti-Xa monitoring in treatment and osteoporosis risk, with comparative efficacy of pre- vs. post-operative administration being debated.

    • Impact:

    • Informs clinical decision-making regarding LMWH use in France.
    • Highlights areas requiring further research and clinical trials.
    • Supports the ongoing evaluation of LMWH in thrombosis management.